Regeneron says it will continue trial of COVID antibody cocktail as latest data show positive results

Regeneron Pharmaceuticals Inc. REGN, -0.29% said initial data from its Phase 1/2/3 clinical trial of its antibody cocktail in hospitalized COVID-19 patients requiring low-flow oxygen passed a futility analysis, meaning there was sufficient efficacy to warrant continuing the trial. "The results passed the futility analysis (p<0.3 one-sided), as seronegative patients treated with the antibody cocktail had a lower risk of death or receiving mechanical ventilation (HR: 0.78; 80% CI: 0.51-1.2),"the company said in a statement.